» Articles » PMID: 27890259

How Important is NK Alloreactivity and KIR in Allogeneic Transplantation?

Overview
Publisher Elsevier
Specialty Hematology
Date 2016 Nov 29
PMID 27890259
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Relapse of acute myelogenous leukemia (AML) after allogeneic hematopoietic cell transplantation (allo HCT) is a major cause of death in transplant recipients. Efforts to control relapse by promoting donor T-cell alloreactivity, such as withdrawal of immune suppression or donor lymphocyte infusions, are limited by the propensity to induce graft versus host disease (GVHD) and by inadequate efficacy. Therefore, options for AML patients who have relapsed AML after allo HCT are few and outcomes are poor. Similar to T-cells, natural killer (NK) cells have potent anti-leukemia effector capacity, and yet unlike T-cells, NK cells do not mediate GVHD. Furthermore, their function does not require matching of human leukocyte antigens (HLA) between donor and recipient. Maximizing donor NK alloreactivity thus holds the exciting possibility to induce the graft versus leukemia (GVL) effect without engendering GVHD. Among the array of activating and inhibitory NK cell surface receptors, the killer Ig-like receptors (KIR) play a central role in modulating NK effector function. Here we will review how KIR mediates donor alloreactivity, discuss the role of KIR gene and allele typing to optimize allo HCT donor selection, and discuss how KIR may aid adoptive NK and other cell therapies.

Citing Articles

Reconstitution of Natural Killer cells after allogeneic hematopoietic stem cell transplantation is facilitated by Huiyang-Guben decoction through activating the Smad7/Stat3 signal pathway.

Gao X, Wang Q, He H, Yang T, Zhang H, Zhao J Mol Cell Biochem. 2023; 479(7):1721-1733.

PMID: 37973706 DOI: 10.1007/s11010-023-04882-1.


Optimizing Blood Stem Cell Transplants Through Cellular Engineering.

Soh K, Hwang W Blood Cell Ther. 2023; 5(1):1-15.

PMID: 36714264 PMC: 9847292. DOI: 10.31547/bct-2021-008.


High-resolution human KIR genotyping.

Downing J, DOrsogna L Immunogenetics. 2022; 74(4):369-379.

PMID: 35050404 PMC: 9262774. DOI: 10.1007/s00251-021-01247-0.


OMIP-080: 29-Color flow cytometry panel for comprehensive evaluation of NK and T cells reconstitution after hematopoietic stem cells transplantation.

Vanikova S, Koladiya A, Musil J Cytometry A. 2021; 101(1):21-26.

PMID: 34693626 PMC: 9298022. DOI: 10.1002/cyto.a.24510.


Immune Reconstitution-Based Score for Risk Stratification of Chronic Graft-Versus-Host Disease Patients.

Serpenti F, Lorentino F, Marktel S, Milani R, Messina C, Greco R Front Oncol. 2021; 11:705568.

PMID: 34367991 PMC: 8341942. DOI: 10.3389/fonc.2021.705568.


References
1.
Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H . Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood. 2016; 128(2):297-312. PMC: 4946205. DOI: 10.1182/blood-2016-03-706317. View

2.
Campbell K, Hasegawa J . Natural killer cell biology: an update and future directions. J Allergy Clin Immunol. 2013; 132(3):536-544. PMC: 3775709. DOI: 10.1016/j.jaci.2013.07.006. View

3.
Forlenza C, Boudreau J, Zheng J, Le Luduec J, Chamberlain E, Heller G . KIR3DL1 Allelic Polymorphism and HLA-B Epitopes Modulate Response to Anti-GD2 Monoclonal Antibody in Patients With Neuroblastoma. J Clin Oncol. 2016; 34(21):2443-51. PMC: 4962735. DOI: 10.1200/JCO.2015.64.9558. View

4.
Bachanova V, Burns L, McKenna D, Curtsinger J, Panoskaltsis-Mortari A, Lindgren B . Allogeneic natural killer cells for refractory lymphoma. Cancer Immunol Immunother. 2010; 59(11):1739-44. PMC: 4082975. DOI: 10.1007/s00262-010-0896-z. View

5.
Rajagopalan S, Long E . KIR2DL4 (CD158d): An activation receptor for HLA-G. Front Immunol. 2012; 3:258. PMC: 3422731. DOI: 10.3389/fimmu.2012.00258. View